Sensome

Sensome is a Paris-based, private medical device innovator founded in 2015, operating in the cardiovascular and interventional medicine sectors. The company has developed a proprietary platform that miniaturizes tissue-sensing via bio-impedance into microchips, which can be integrated into standard minimally invasive devices to provide real-time tissue characterization. Its lead product, the Clotild® Smart Guidewire System for acute ischemic stroke, is in the regulatory stage targeting EU, US, and Japanese markets, with additional clinical-stage programs in lung cancer biopsy and peripheral vascular intervention. Sensome represents a novel approach to data-driven interventional care, backed by strategic manufacturing partners like Asahi Intecc and a consortium of investors.

Miniaturized bio-impedance microchip sensor integrated into minimally invasive devices for real-time tissue characterization and differentiation.

In neurovascular, Clotild competes indirectly with standard 'dumb' guidewires and other thrombectomy adjuvants, but has no direct competitor offering real-time clot characterization. In lung biopsy, it would compete with navigation platforms like Ion (Intuitive) and Monarch (Johnson & Johnson) as well as confirmation tools like radial EBUS. In PVD, it faces competition from advanced imaging guidewires (IVUS, OCT) and specialized crossing devices. Its unique value is real-time, localized tissue data without requiring imaging agents or separate imaging systems.